Skip to search formSkip to main contentSkip to account menu

OSI 211

Known as: OSI-211, OSI211 
National Institutes of Health

Related topics

Related topics

4 relations
GI 147211NX 211

Broader (2)

lurtotecanlurtotecan liposome

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of…
PURPOSE Liposomal lurtotecan (OSI-211) is a liposomal formulation of the water-soluble topoisomerase I inhibitor lurtotecan… 
2005
2005
Phase I study of OSI-211 (liposomal lurtotecan) in combination with liposomal doxorubicin (LD) every 3 weeks in patients (pts) with advanced solid tumors; final analysis suggests benefit in…
2074 Background: OSI-211 is a topoisomerase (topo) I inhibitor in liposomal formulation. In vivo efficacy of the liposomal… 
2005
2005
P-789 Phase II study of OSI-211 (liposomal lurtotecan) in recurrentsmall-cell lung cancer (SCLC)
2005
2005
Randomised Trial of Two Intravenous Schedules of the Liposomal Topoisomerase I Inhibitor, OSI-211, in Women With Relapsed Epithelial Ovarian Cancer. A Trial of the National Cancer Institute of Canada…
2004
2004
A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
Purpose: To define the maximum tolerated dose (MTD), recommended phase II dose (RD) and dose limiting toxicity (DLT) of liposomal… 
2004
2004
Phase I and pharmacokinetic study of a low‐clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia
OSI‐211 is a low‐clearance, unilamellar liposomal formulation of a water‐soluble camptothecin analogue, lurtotecan. OSI‐211 has… 
2004
2004
Phase I study to evaluate the safety, tolerability and pharmacokinetics of OSI-211 (Liposomal Lurtotecan) in combination with Carboplatin
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)